Table 1.

Gag-specific CTL responses in Boston cohorts studied

Best-recognized peptideSubjectHLA class I typeRacial groupCTL (per one million PBMCs)Defined dominant epitope [HLA restriction]a
p17.2A014-TCHA*0201/3 B35/44 Cw1/4African American Caucasoid600RLRPGGKKK [A3]
019-TCHA3/*3001 B51/60 CW15/16Caucasoid723KIRLRPGGK [A3]
027-TCHA1/*0201 B18/57 Cw6/7Caucasoid472WEKIRLRPGGKKKYK [NDb]
048-TCHA1/*0201 B27/37 Cw2/6Caucasoid780IRLRPGGKK [B27]
049-TCHA1/24 B27/37 Cw1/6Caucasoid170IRLRPGGKK [B27]
004-BMCA3/*3001 B7/35 Cw4/7Haitian273KIRLRPGGK [A3]
011-BMCA24/29 B7/45 Cw6/7African American170RLRPGGKKKYK [ND]
96/00600A3/11 B44/62 Cw3/5Caucasoid225WEKIRLRPGGKKKYK [ND]
96/01114A2/3 B35/- Cw4/-Caucasoid>1,000RLRPGGKKK [A3]
85/00003A*0201/3 B7/51 Cw7/-Caucasoid>1,000RLRPGGKKK [A3]
JCA*0201/3 B35/55 Cw-/-Caucasoid880RLRPGGKKK [A3]
GVA*0201/3 B8/62 Cw7/10Caucasoid280RLRPGGKKK [A3]
TDA3/68 B35/44 Cw4/7Caucasoid1,280RLRPGGKKK [A3]
p17.4A042-TCHA3/33 B35/53 Cw4/-African American>1,000WASRELERF [ND]
p17.8001-UNCA*0201/74 B7/35 Cw7/16African American2,800SLYNTVATL [A*0201]
004-TCHA*0202/29 B7/44 Cw7/16Caucasoid Hispanic1,400SLYNTVATL [A*0202]
032-TCHA*0201/23 B44/61 Cw2/4Caucasoid160SLYNTVATL [A*0201]
034-TCHA*0201/68 B35/44 Cw4/7Caucasoid120SLYNTVATL [A*0201]
036-TCHA*0201/68 B18/51 Cw5/16Haitian213SLYNTVATL [A*0201]
040-TCHA*0201/34 B7/52 Cw7/16Haitian400SLYNTVATL [A*0201]
007-BMCA*0201/23 B14/45 Cw6/8African American520SLYNTVATL [A*0201]
010-161jA*0201/3 B7/60 Cw3/7Caucasoid>2,000SLYNTVATL [A*0201]
9354A*0201/3 B7/35 Cw4/7Caucasoid5,600SLYNTVATL [A*0201]
013-661A1/*0201 B44/52 Cw-/-Caucasoid920SLYNTVATL [A*0201]
85/00003A*0201/3 B7/51 Cw7/-Caucasoid>1,000SLYNTVATL [A*0201]
p17.8A013-199A*0201/*3002 B44/51 Cw-/-Caucasoid5,650RSLYNTVATLY [A*3002]
p17.9A028-BMCA1/*0201 B8/63 Cw7/-Caucasoid>1,000DVKDTKEAL [ND]
045-TCHA23/68 B45/72 Cw2/16Haitian133RIDVKDTKEAL [ND]
p24.2033-BMCA34/68 B57/71 Cw3/7Haitian500VQHAISPRTLNAWV [ND]
p24.3GSA*0201/30 B44/57 Cw-/-Caucasoid770KAFSPEVIPMF [B57]
p24.5015-TCHA*3002/68 B14/*5802 Cw6/8African American462GATPQDLNTMLNTV [ND]
016-TCHA*3001/- B42/- Cw17/-African American507TPQDLNTML [B42]
044-TCHA*0201/30 B42/52 Cw16/17African American1,450TPQDLNTML [B42]
009-BMCA*0201/*3002 B14/27 Cw1/8African American360TPQDLNTML [B14/Cw8]
021-BMCA3/*3001 B42/- Cw17/-African American>1,000TPQDLNTML [B42]
026-BMCA3/- B42/*5703 Cw7/17Hispanic2,460TPQDLNTML [B42]
032-BMCA1/80 B42/45 Cw16/17African American1,810TPQDLNTML [B42]
94/00181A11/24 B14/44 Cw8/16Caucasoid>1,000TPQDLNTML [ND]
p24.13029-TCHA*0201/32 B7/8 Cw7/15Caucasoid433EIYKRWII [B8]
p24.14023-TCHA23/26 B62/72 Cw2/3African American660GLNKIVRMY [B62]
043-TCHNDAfrican American1,500KRWILGLNKIVRMY [ND]
p24.17KMA3/- B14/60 Cw3/8Caucasoid1,600DRFYKTLRA [B14]
JFMA*0201/68 B14/44 Cw5/8Caucasoid120DRFYKTLRA [B14]
p24.22KSA3/- B7/- Cw7/-Caucasoid1,020GPSHKARVL [B7]
DKA*0201/11 B18/44 Cw-/-Caucasoid1,300ACQGVGGPGHK [A11]
  • a In each case the defined epitopes shown represent the HLA restriction, and epitope optimization was determined for each subject. Optimized epitopes described elsewhere (for example, WASRELERF as a B35-restricted epitope [10]) are not shown unless the response was demonstrated in the subjects studied.

  • b ND, not determined.